1st Quarter - Report

BROWNSTEIN HYATT FARBER SCHRECK, LLP for NOVARTIS

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
$50,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report (this page) Apr 20, 2020 $50,000 Replaced
1st Quarter - Amendment Jul 8, 2020 $50,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases H.R. 748 CARES Act, Issues related to COVID-19 treatment

LobbyistCovered position, as disclosed
NADEAM ELSHAMI —
EMILY FELDER —
MARC LAMPKIN —
BRIAN MCKEON —
RADHA MOHAN —
JEROME MURRAY —
ZACHARY PFISTER —
BRIAN WILD —

Contacted: Executive Office of the President (EOP); Office of the Vice President of the United States; HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 748 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.